Determinants of the prevalence of gout in the general population: a systematic review and meta-regression

European Journal of Epidemiology

Volumn 30, Issue 1, 2015, Pages 19-33

  Wijnands, José M A ^a,b   Viechtbauer, Wolfgang ^b   Thevissen, Kristof ^a   Arts, Ilja C W ^b,c   Dagnelie, Pieter C ^b,c   Stehouwer, Coen D A ^a,c   van der Linden, Sjef ^a,b   Boonen, Annelies ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Gout; Incidence; Meta regression; Prevalence; Systematic review

Indexed keywords

ADOLESCENT; ADULT; FEMALE; GOUT; HEALTH SURVEY; HUMAN; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE;

ADOLESCENT; ADULT; FEMALE; GOUT; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PREVALENCE;

EID: 84930521007     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-014-9927-y     Document Type: Review

References (102)

1. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012;125:679–87. doi:10.1016/j.amjmed.2011.09.033.
2. Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology. 2007;46:1441–4.
3. Hamburger M, Baraf HS, Adamson TC 3rd, Basile J, Bass L, Cole B, et al. 2011 Recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med. 2011;123:3–36. doi:10.3810/pgm.2011.11.2511.
4. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006;8:S2.
5. Singh JA. Racial and gender disparities among patients with gout. Curr Rheumatol Rep. 2013;15:307. doi:10.1007/s11926-012-0307-x.
6. Doherty M. New insights into the epidemiology of gout. Rheumatology. 2009;48:2–8.
7. Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. Am J Manag Care. 2005;11:S435–42.
8. Miller DR, Rogers WH, Kazis LE, Spiro A 3rd, Ren XS, Haffer SC. Patients’ self-report of diseases in the Medicare Health Outcomes Survey based on comparisons with linked survey and medical data from the Veterans Health Administration. J Ambul Care Manage. 2008;31:161–77. doi:10.1097/01.JAC.0000314707.88160.9c.
9. Malik A, Dinnella JE, Kwoh CK, Schumacher HR. Poor validation of medical record ICD-9 diagnoses of gout in a Veterans Affairs Database. J Rheumatol. 2009;36:1283–6.
10. Cheng LSC, Chiang SL, Tu HP, Chang SJ, Wang TN, Ko AMJ, et al. Genomewide scan for gout in Taiwanese aborigines reveals linkage to chromosome 4q25. Am J Hum Genet. 2004;75:498–503.
11. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for meta-analysis in medical research. New York: Wiley; 2000.
12. Lipsey MW, Wilson DB. Practical meta-analysis. Thousand Oaks, CA: Sage; 2001.
13. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549. doi:10.1136/bmj.d549.
14. Berkey CS, Hoaglin DC, Mosteller F, Colditz GA. A random-effects regression model for meta-analysis. Stat Med. 1995;14:395–411.
15. Greenland S, O’Rourke K. On the bias produced by quality scores in meta-analysis, and a hierarchical view of proposed solutions. Biostatistics. 2001;2:463–71. doi:10.1093/biostatistics/2.4.463.
16. Raudenbush SW. Analyzing effect sizes: random-effects models. In: Cooper H, Hedges LV, Valentine JC, editors. The handbook of research synthesis and meta-analysis. 2nd ed. New York: Russell Sage Foundation; 2009. p. 295–315.
17. Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. Stat Med. 2003;22:2693–710. doi:10.1002/sim.1482.
18. Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist. 1979;6:65–70.
19. Viechtbauer W. Conducting meta-analyses in R with the metafor Package. J Stat Softw. 2010;36:1–48.
20. Bates D, Maechler M, Bolker B, Walker S. lme4: Linear mixed-effects models using Eigen and S4. R package version 1.1–6 2014. http://CRAN.R-project.org/package=lme4.
21. Yee TW. The VGAM package for categorical data analysis. J Stat Softw. 2010;32:1–34.
22. Akizuki S. A population study of hyperuricaemia and gout in Japan–analysis of sex, age and occupational differences in thirty-four thousand people living in Nagano Prefecture. Ryumachi. 1982;22:201–8.
23. Al-Arfaj AS. Hyperuricemia in Saudi Arabia. Rheumatol Int. 2001;20:61–4.
24. Alvarez Nemegyei J, Nuno Gutierrez BL, Alcocer Sanchez JA. Enfermedades reumaticas y discapacidad laboral en poblacion adulta rural. Rev Med Inst Mex Seguro Soc. 2005;43:287–92.
25. Anagnostopoulos I, Zinzaras E, Alexiou I, Papathanasiou AA, Davas E, Koutroumpas A, et al. The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet Disord. 2010;11:98. doi:10.1186/1471-2474-11-98.
26. Andrianakos A, Trontzas P, Christoyannis F, Dantis P, Voudouris C, Georgountzos A, et al. Prevalence of rheumatic diseases in Greece: a cross-sectional population based epidemiological study. The ESORDIG Study. J Rheumatol. 2003;30:1589–601.
27. Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis. 2008;67:960–6.
28. Badley EM, Meyrick JS, Wood PH. Gout and serum uric acid levels in the Cotswolds. Rheumatol Rehabil. 1978;17:133–42.
29. Beighton P, Solomon L, Soskolne CL, Sweet MB. Rheumatic disorders in the South African Negro. Part IV. Gout and hyperuricaemia. S Afr Med J. 1977;51:969–72.
30. Beighton P, Valkenburg HA. Bone and joint disorders on Tristan da Cunha. S Afr Med J. 1974;48:743–7.
31. Bergmann MM, Jacobs EJ, Hoffmann K, Boeing H. Agreement of self-reported medical history: comparison of an in-person interview with a self-administered questionnaire. Eur J Epidemiol. 2004;19:411–6.
32. Bergstrom G, Bjelle A, Sorensen LB, Sundh V, Svanborg A. Prevalence of rheumatoid arthritis, osteoarthritis, chondrocalcinosis and gouty arthritis at age 79. J Rheumatol. 1986;13:527–34.
33. Boyer GS, Lanier AP, Templin DW. Prevalence rates of spondyloarthropathies, rheumatoid arthritis, and other rheumatic disorders in an Alaskan Inupiat Eskimo population. J Rheumatol. 1988;15:678–83.
34. Brauer GW, Prior IA. A prospective study of gout in New Zealand Maoris. Ann Rheum Dis. 1978;37:466–72.
35. Cakir N, Pamuk ON, Dervis E, Imeryuz N, Uslu H, Benian O, et al. The prevalences of some rheumatic diseases in western Turkey: Havsa study. Rheumatol Int. 2012;32:895–908. doi:10.1007/s00296-010-1699-4.
36. Cardiel MH, Rojas-Serrano J. Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol. 2002;20:617–24.
37. Chaiamnuay P, Darmawan J, Muirden KD, Assawatanabodee P. Epidemiology of rheumatic disease in rural Thailand: a WHO-ILAR COPCORD study. Community Oriented Programme for the Control of Rheumatic Disease. J Rheumatol. 1998;25:1382–7.
38. Chang SJ, Ko YC, Wang TN, Chang FT, Cinkotai FF, Chen CJ. High prevalence of gout and related risk factors in Taiwan’s Aborigines. J Rheumatol. 1997;24:1364–9.
39. Chen SL, Du H, Wang Y, Xu LQ. The epidemiology study of hyperuricemia and gout in a community population of Huangpu District in Shanghai. Chin Med J. 1998;111:228–30.
40. Chopra A, Patil J, Billempelly V, Relwani J, Tandle HS. Prevalence of rheumatic diseases in a rural population in western India: a WHO-ILAR COPCORD Study. J Assoc Physicians India. 2001;49:240–6.
41. Chou CT, Lai JS. The epidemiology of hyperuricaemia and gout in Taiwan aborigines. Br J Rheumatol. 1998;37:258–62.
42. Chou CT, Pei L, Chang DM, Lee CF, Schumacher HR, Liang MH. Prevalence of rheumatic diseases in Taiwan: a population study of urban, suburban, rural differences. J Rheumatol. 1994;21:302–6.
43. Chuang SY, Lee SC, Hsieh YT, Pan WH. Trends in hyperuricemia and gout prevalence: nutrition and health survey in Taiwan from 1993–1996 to 2005–2008. Asia Pac J Clin Nutr. 2011;20:301–8.
44. Currie WJ. Prevalence and incidence of the diagnosis of gout in Great Britain. Ann Rheum Dis. 1979;38:101–6.
45. Dai SM, Han XH, Zhao DB, Shi YQ, Liu Y, Meng JM. Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis, and gout in Shanghai, China: a COPCORD study. J Rheumatol. 2003;30:2245–51.
46. Dans LF, TankehTorres S, Amante CM, Penserga EG. The prevalence of rheumatic diseases in a Filipino urban population: a WHO-ILAR COPCORD study. J Rheumatol. 1997;24:1814–9.
47. Darmawan J, Valkenburg HA, Muirden KD, Wigley RD. The epidemiology of gout and hyperuricemia in a rural population of Java. J Rheumatol. 1992;19:1595–9.
48. Davatchi F, Jamshidi AR, Banihashemi AT, Gholami J, Forouzanfar MH, Akhlaghi M, et al. Effect of ethnic origin (Caucasians versus Turks) on the prevalence of rheumatic diseases: a WHO-ILAR COPCORD urban study in Iran. Clin Rheumatol. 2009;28:1275–82.
49. Douglas WA. Rheumatic disease in the Australian Aborigine of Cape York Peninsula: a 1965 study. APLAR J Rheumatol. 2004;7:237–41. doi:10.1111/j.1479-8077.2004.00098.x.
50. Elliot AJ, Cross KW, Fleming DM. Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994–2007. Ann Rheum Dis. 2009;68:1728–33.
51. Farooqi A, Gibson T. Prevalence of the major rheumatic disorders in the adult population of north Pakistan. Br J Rheumatol. 1998;37:491–5.
52. Gardner MJ, Power C, Barker DJ, Padday R. The prevalence of gout in three English towns. Int J Epidemiol. 1982;11:71–5.
53. Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med. 1967;42:27–37.
54. Hanova P, Pavelka K, Dostal C, Holcatova I, Pikhart H. Epidemiology of rheumatoid arthritis, juvenile idiopathic arthritis and gout in two regions of the Czech Republic in a descriptive population-based survey in 2002–2003. Clin Exp Rheumatol. 2006;24:499–507.
55. Haq SA, Darmawan J, Islam MN, Uddin MZ, Das BB, Rahman F, et al. Prevalence of rheumatic diseases and associated outcomes in rural and urban communities in Bangladesh: a COPCORD study. J Rheumatol. 2005;32:348–53.
56. Harris CM, Lloyd D, Lewis J. Prevalence and Prophylaxis of Gout in England. J Clin Epidemiol. 1995;48:1153–8.
57. Hoa TTM, Damarwan J, Le CS, Hung NV, Nhi CT, An TN. Prevalence of the rheumatic diseases in urban Vietnam: a WHO-ILAR COPCORD study. J Rheumatol. 2003;30:2252–6.
58. Jackson L, Taylor R, Faaiuso S, Ainuu SP, Whitehouse S, Zimmet P. Hyperuricaemia and gout in Western Samoans. J Chronic Dis. 1981;34:65–75.
59. Joshi VL, Chopra A. Is there an urban-rural divide? Population surveys of rheumatic musculoskeletal disorders in the Pune region of India using the COPCORD Bhigwan Model. J Rheumatol. 2009;36:614–22.
60. Kato H, Duff IF, Russell WJ, Uda Y, Hamilton HB, Kawamoto S, et al. Rheumatoid arthritis and gout in Hiroshima and Nagasaki, Japan: a prevalence and incidence study. J Chronic Dis. 1971;23:659–79.
61. Klemp P, Stansfield SA, Castle B, Robertson MC. Gout is on the increase in New Zealand. Ann Rheum Dis. 1997;56:22–6.
62. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988–1994. Am J Kidney Dis. 2002;40:37–42.
63. Li R, Sun J, Ren LM, Wang HY, Liu WH, Zhang XW, et al. Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. Rheumatology. 2012;51:721–9. doi:10.1093/rheumatology/ker370.
64. Mahajan A, Jasrotia DS, Manhas AS, Jamwal SS. Prevalence of major rheumatic disorders in Jammu. JK Sci. 2003;5:63–6.
65. Miao ZM, Li CG, Chen Y, Zhao SH, Wang YG, Wang ZC, et al. Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J Rheumatol. 2008;35:1859–64.
66. Mikkelsen WM, Dodge HJ, Duff IF, Kato H. Estimates of the prevalence of rheumatic diseases in the population of Tecumseh, Michigan, 1959–60. J Chronic Dis. 1967;20:351–69.
67. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR, Saag KG. Gout epidemiology: results from the UK general practice research database, 1990–1999. Ann Rheum Dis. 2005;64:267–72.
68. Minaur N, Sawyers S, Parker J, Darmawan J. Rheumatic disease in an Australian aboriginal community in North Queensland, Australia. A WHO-ILAR COPCORD survey. J Rheumatol. 2004;31:965–72.
69. Nan HR, Qiao Q, Dong YH, Gao WG, Tang B, Qian RL, et al. The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China. J Rheumatol. 2006;33:1346–50.
70. Obregon-Ponce A, Iraheta I, Garcia-Ferrer H, Mejia B, Garcia-Kutzbach A. Prevalence of musculoskeletal diseases in Guatemala, Central America: the COPCORD study of 2 populations. J Clin Rheumatol. 2012;18:170–4. doi:10.1097/RHU.0b013e3182583803.
71. O’Sullivan JB. Gout in a New England town. A prevalence study in Sudbury, Massachusetts. Ann Rheum Dis. 1972;31:166–9.
72. Pelaez-Ballestas I, Sanin LH, Moreno-Montoya J, Alvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M, et al. Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J Rheumatol. 2011;86:3–8. doi:10.3899/jrheum.100951.
73. Picavet HS, Hazes JM. Prevalence of self reported musculoskeletal diseases is high. Ann Rheum Dis. 2003;62:644–50.
74. Popert AJ, Hewitt JV. Gout and hyperuricaemia in rural and urban populations. Ann Rheum Dis. 1962;21:154–63.
75. Portis AJ, Laliberte M, Tatman P, Moua M, Culhane-Pera K, Maalouf NM, et al. High prevalence of gouty arthritis among the Hmong population in Minnesota. Arthritis Care Res (Hoboken). 2010;62:1386–91. doi:10.1002/acr.20232.
76. Prior IA, Rose BS, Harvey HP, Davidson F. Hyperuricaemia, gout, and diabetic abnormality in Polynesian people. Lancet. 1966;1:333–8.
77. Reyes-Llerena GA, Guibert-Toledano M, Penedo-Coello A, Perez-Rodriguez A, Baez-Duenas RM, Charnicharo-Vidal R, et al. Community-based study to estimate prevalence and burden of illness of rheumatic diseases in Cuba: a COPCORD study. J Clin Rheumatol. 2009;15:51–5.
78. Rose BS, Prior IA. A survey of rheumatism in a rural New Zealand Maori community. Ann Rheum Dis. 1963;22:410–5.
79. Salaffi F, De Angelis R, Grassi W. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol. 2005;23:819–28.
80. Sari I, Akar S, Pakoz B, Sisman AR, Gurler O, Birlik M, et al. Hyperuricemia and its related factors in an urban population, Izmir, Turkey. Rheumatol Int. 2009;29:869–74.
81. Steven MM. Prevalence of chronic arthritis in four geographical areas of the Scottish Highlands. Ann Rheum Dis. 1992;51:186–94.
82. Sullivan FM, Barber JH, Sturrock RD. Rheumatology at the general practitioner/hospital interface: a study of prevalence and access to specialist care. Ann Rheum Dis. 1990;49:983–5.
83. Taylor W, Smeets L, Hall J, McPherson K. The burden of rheumatic disorders in general practice: consultation rates for rheumatic disease and the relationship to age, ethnicity, and small-area deprivation. N Z Med J. 2004;117:U1098.
84. Trifiro G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study. Ann Rheum Dis. 2012;72:694–700. doi:10.1136/annrheumdis-2011-201254.
85. Veerapen K, Wigley RD, Valkenburg H. Musculoskeletal pain in Malaysia: a COPCORD survey. J Rheumatol. 2007;34:207–13.
86. Wigley R, Manahan L, Muirden KD, Caragay R, Pinfold B, Couchman KG, et al. Rheumatic disease in a Philippine village II: a WHO-ILAR-APLAR COPCORD study, phases II and III. Rheumatol Int. 1991;11:157–61.
87. Winnard D, Wright C, Taylor WJ, Jackson G, Te Karu L, Gow PJ, et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology. 2012;51:901–9. doi:10.1093/rheumatology/ker361.
88. Zalokar J, Lellouch J, Claude JR, Kuntz D. Serum uric acid in 23,923 men and gout in a subsample of 4257 men in France. J Chronic Dis. 1972;25:305–12.
89. Zeng QY, Wang QW, Chen R, Xiao ZG, Huang SB, Xu JC. Primary gout in Shantou: a clinical and epidemiological study. Chin Med J. 2003;116:66–9.
90. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63:3136–41. doi:10.1002/art.30520.
91. Zimmet PZ, Whitehouse S, Jackson L, Thoma K. High prevalence of hyperuricaemia and gout in an urbanised Micronesian population. Br Med J. 1978;1:1237–9.
92. Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol. 2000;27:1045–50.
93. Arromdee E, Michet CJ, Crowson CS, O’Fallon WM, Gabriel SE. Epidemiology of gout: Is the incidence rising? J Rheumatol. 2002;29:2403–6.
94. Bhole V, de Vera M, Rahman MM, Krishnan E, Choi H. Epidemiology of female gout: 52-Year follow-up of a prospective cohort. Arthritis Rheum. 2010;62:1069–76.
95. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82:421–6.
96. Isomaki H, Raunio J, von Essen R, Hameenkorpi R. Incidence of inflammatory rheumatic diseases in Finland. Scand J Rheumatol. 1978;7:188–92.
97. O’Sullivan JB. The incidence of gout and related uric acid levels in Sudbury, Massachusetts. In: Bennett PH, Wood PHN, editors. Population studies of the rheumatic diseases. Amsterdam: Excerpta Medica; 1968. p. 371–6.
98. Cea Soriano L, Rothenbacher D, Choi HK, Garcia Rodriguez LA. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther. 2011;R13:39. doi:10.1186/ar3272.
99. Robinson P, Taylor W, Merriman T. A systematic review of the prevalence of gout and hyperuricemia in Australia. Intern Med J. 2012;42:997–1007. doi:10.1111/j.1445-5994.2012.02794.x.
100. Torralba TP, Bayani Sioson PS. The Filipino and gout. Semin Arthritis Rheum. 1975;4:307–20.
101. Hochberg MC, Thomas J, Thomas DJ, Mead L, Levine DM, Klag MJ. Racial differences in the incidence of gout. The role of hypertension. Arthritis Rheum. 1995;38:628–32.
102. McAdams MA, Maynard JW, Baer AN, Kottgen A, Clipp S, Coresh J, et al. Reliability and sensitivity of the self-report of physician-diagnosed gout in the campaign against cancer and heart disease and the atherosclerosis risk in the community cohorts. J Rheumatol. 2011;38:135–41. doi:10.3899/jrheum.100418.